Axsome Therapeutics, Inc.
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares of Axsome Therapeutics, Inc. (AXSM) at an average of $212.19 ($212.01–$213.95, $10.54M total) across 2 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
The article highlights Axsome Therapeutics (AXSM) and Moderna (MRNA) as stocks expected to perform despite macro and geopolitical risks. For AXSM, Q1 revenue rose 57% to $191.2M, but operating loss widened to $63.4M. It cites FDA acceptance for AXS-12, with potential approval by May 2027. For MRNA, it notes FDA panel support for mFLUSIVA and Q2 revenue of $145M, up 2% YoY.
Analysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
Over the past 7 days, alphai's AI scored 1 news story mentioning AXSM (Axsome Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AXSM coverage spans insider activity, financial news and technology.
In the last 30 days, AXSM insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($10.5M). The most active reporter was TABUTEAU HERRIOT, Chief Executive Officer, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Insider selling is a near-term sentiment signal, but the disclosed 10b5-1 plan reduces the likelihood of immediate fundamental interpretation.
FDA acceptance and a defined 2027 approval target can re-rate AXSM’s late-stage probability and extend the revenue optionality narrative.
New bullish initiation may attract incremental flows, but without new company disclosures it is more sentiment than substance.
FDA acceptance and a defined PDUFA date reduce regulatory uncertainty and set a clear catalyst window for AXS-12.
This sets a concrete earnings-event date, which can drive positioning, implied volatility, and pre-announcement expectations.
alphai scores every news story that mentions AXSM with an AI model for sentiment and relevance, and aggregates insider trades from Axsome Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares of Axsome Therapeutics, Inc. (AXSM) at an average of $212.19 ($212.01–$213.95, $10.54M total) across 2 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readThe article highlights Axsome Therapeutics (AXSM) and Moderna (MRNA) as stocks expected to perform despite macro and geopolitical risks. For AXSM, Q1 revenue rose 57% to $191.2M, but operating loss widened to $63.4M. It cites FDA acceptance for AXS-12, with potential approval by May 2027. For MRNA, it notes FDA panel support for mFLUSIVA and Q2 revenue of $145M, up 2% YoY.
6 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min readAxsome Therapeutics (NASDAQ: AXSM) said the FDA accepted for filing its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and indicated it does not plan an advisory committee meeting. AXS-12 is not yet approved by the FDA.
2 min readAxsome Therapeutics (NASDAQ: AXSM) said it will release its second-quarter 2026 financial results on Aug. 10, 2026, before U.S. market open. Management will host a conference call at 8:00 a.m. ET and provide a business update. The company also noted a webcast and a 30-day replay on its website.
2 min readAxsome Therapeutics (NASDAQ: AXSM) said the first patient was dosed in its FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD (ages 6 to <12). The randomized, double-blind, placebo-controlled study will enroll ~468 patients into two solriamfetol doses or placebo for 6 weeks; the primary endpoint is change in ADHD-RS-5 total score at week 6. The company also noted FOCUS-3 for adolescents.
2 min readTABUTEAU HERRIOT (Chief Executive Officer) sold 49,666 shares of Axsome Therapeutics, Inc. (AXSM) at $240.25 ($11.93M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readForbes’ InnovationRx says Axsome Therapeutics’ stock doubled in nine months, lifting market cap from $6.1B to $12.6B, after FDA approval of Auvelity for Alzheimer’s agitation. Axsome reported $709M revenue for the latest 12 months (+64%) and forecasts peak Auvelity sales of $8B. It also acquired epilepsy and schizophrenia/Tourette candidates. Separately, HistoSonics’ Edison histotripsy tech and a Medicaid work-rule lawsuit are discussed.
7 min readAxsome Therapeutics shares hit a new 52-week high in mid-day trading Thursday after TD Cowen raised its price target to $300 from $275 and kept a buy rating. The stock traded up to $260.19 and last at $249.73. Other analysts also adjusted targets. CEO Herriot Tabuteau sold 49,670 shares at $241.01 on June 9.
4 min readAxsome Therapeutics, Inc. (AXSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 axsm-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan ARTICLE I Statement of Purpose and Effective Date 1.01 Purpose . Axsome Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Axsome ”), here
2 min read
